Drug Profile
Mobilan - Panacela Labs
Alternative Names: M-VM3; MVAME03; Prostate cancer vaccine - Pancela/Statera BiopharmaLatest Information Update: 17 Oct 2021
Price :
$50
*
At a glance
- Originator Childrens Cancer Institute Australia for Medical Research; Cleveland BioLabs; Cleveland Clinic; Roswell Park Cancer Institute
- Developer Panacela Labs
- Class Antineoplastics; Cancer vaccines
- Mechanism of Action Toll-like receptor 5 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Prostate cancer
Most Recent Events
- 11 Oct 2021 Phase I/II development is ongoing in Russia (Panacela Labs website, October 2021)
- 01 Sep 2021 Cytocom is now called Statera BioPharma
- 28 Jul 2021 Cytocom has been merged with Cleveland BioLabs to form Cytocom